Idioma:

Efficacy and safety of 800 and 1200 mg eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures

Gil-Nagel, A. ; Lopes-Lima, J. ; Almeida, L. ; Maia, J. ; Soares-da-Silva, P.

Acta neurologica Scandinavica, 2009-11, Vol.120 (5), p.281-287 [Periódico revisado por pares]

Oxford, UK: Blackwell Publishing Ltd

Texto completo disponível

Citações Citado por

Enviar para

Título:
Efficacy and safety of 800 and 1200 mg eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures
Autor: Gil-Nagel, A. ; Lopes-Lima, J. ; Almeida, L. ; Maia, J. ; Soares-da-Silva, P.
Assuntos: adjunctive therapy ; Adolescent ; Adult ; Adverse Drug Reaction Reporting Systems ; Aged ; Anticonvulsants - administration & dosage ; Anticonvulsants - adverse effects ; Anticonvulsants - therapeutic use ; antiepileptic drugs ; Biological and medical sciences ; Cranial nerves. Spinal roots. Peripheral nerves. Autonomic nervous system. Gustation. Olfaction ; Dibenzazepines - administration & dosage ; Dibenzazepines - adverse effects ; Dibenzazepines - therapeutic use ; Dizziness - chemically induced ; Dose-Response Relationship, Drug ; Double-Blind Method ; Epilepsies, Partial - drug therapy ; epilepsy ; eslicarbazepine acetate ; Female ; Headache - chemically induced ; Humans ; Maia ; Male ; Medical sciences ; Middle Aged ; Nausea - chemically induced ; Nervous system (semeiology, syndromes) ; Neurology ; partial-onset seizures ; Patient Selection ; Placebos ; Seizures - drug therapy ; Treatment Outcome
É parte de: Acta neurologica Scandinavica, 2009-11, Vol.120 (5), p.281-287
Notas: ArticleID:ANE1218
istex:53DB662AAB52F37669D3415174EE60D9E10B6928
ark:/67375/WNG-RBCS2D46-2
ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
Descrição: Objectives – To evaluate the efficacy and safety of eslicarbazepine acetate (ESL) as adjunctive therapy in adults with partial‐onset seizures. Material and methods – Double‐blind, placebo‐controlled, parallel‐group, multicenter study consisting of an 8‐week baseline period, after which patients were randomized to placebo (n = 87) or once‐daily ESL 800 mg (n = 85) or 1200 mg (n = 80). Patients received half dose during 2 weeks preceding a 12‐week maintenance period. Results – Seizure frequency over the maintenance period was significantly (P < 0.05) lower than placebo in both ESL groups. Responder rate was 23% (placebo), 35% (800 mg), and 38% (1200 mg). Median relative reduction in seizure frequency was 17% (placebo), 38% (800 mg), and 42% (1200 mg). The most common adverse events (AEs) (>10%) were dizziness, somnolence, headache, and nausea. The majority of AEs were of mild or moderate severity. Conclusions – Once‐daily treatment with ESL 800 and 1200 mg was effective and generally well tolerated.
Editor: Oxford, UK: Blackwell Publishing Ltd
Idioma: Inglês

Links

Voltar para lista de resultados

Realização: Logos de Redes Sociais:

Efficacy and safety of 800 and 1200 mg eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures

Gil-Nagel, A. ; Lopes-Lima, J. ; Almeida, L. ; Maia, J. ; Soares-da-Silva, P.

Oxford, UK: Blackwell Publishing Ltd

Buscando em bases de dados remotas. Favor aguardar.